×

product

Tirzepatide

  • CAS: 2023788-19-2
  • MF: C225H348N48O68
  • MW: 4813
  • OEM ODM available

    Feature

    Tirzepatide is the first GIP/GLP1 receptor co-agonist used in clinical practice. It retains 9 homologous amino acids of GIP and 10 amino acids shared by GIP and GLP-1.
    Tirzepatide is effective in weight loss and is superior to single use of GLP-1 agonists such as Semaglutide.
    Tirzepatide has become a potential drug for the treatment of metabolic diseases due to its innovative dual-target mechanism and significant efficacy.

    Function and Application

    1. Tirzepatide is an ideal choice for obesity management.
    2. Tirzepatide shows good weight loss, blood sugar lowering and metabolic regulation effects in patients with type 2 diabetes.

    It works in the following ways:
    (1) Enhances glucose-dependent insulin secretion and inhibits glucagon release.
    (2) Increases satiety and regulates appetite.
    (3) GIP works synergistically with GLP-1 to reduce calorie intake.

    Specification-COA

    Tests SpecificationsResults
    AppearanceWhite powderConforms
    SolubilitySoluble in waterConforms
    Purity(HPLC)≥98.0%99.11%
    Related Substance(HPLC)Any individual impurity≤1.0%0.37%
    Amino Acid analysisAsp 1.6~2.42
    Tyr 1.6~2.42
    Lys 1.6~2.42.1
    Ile 2.0~3.22
    Leu 1.6~2.42
    Val 0.8~1.21
    Thr 1.6~2.42
    Phe 1.6~2.42
    Ser 4.0~6.04.5
    Ala 3.2~4.84
    Gly 3.2~4.84
    Glu 3.2~4.84.3
    Pro 3.2-4.83.4
    Aib N/A/
    AEEA N/A/
    Sodium salt<5.0%0.83%
    Peptide Content≥85.0%92.31%
    Water Content (Karl Fischer)≤10.0%3.56%
    Residual solventsAcetonitrile NMT 410ppmConforms
    Methanol NMT 3000ppmConforms
    Bacterial endotoxin<10EU/mgConforms
    Microbial LimitsTotal aerobic microbial count ≤1000cfu/gConforms
    Total yeast and mold count ≤200cfu/gConforms
    MS (ESI)4813.45±1.04813.19
    Assay(HPLC)95.0~105.0%(on anhydrous and salt-free substance basis)100.10%

    Related Products

    View All